Seeking Alpha

More on Valeant Pharma Q4: Bausch + Lomb lifts earnings

  • Valeant Pharma (VRX) swings to a net profit of $123.8M from a loss of $89.1M a year earlier, with earnings boosted by the acquisition of Bausch + Lomb.
  • The latest results include charges of $128M mainly related to the acquisition of Bausch + Lomb.
  • Same-store organic product sales +6%.
  • Valeant reaffirms 2014 guidance for EPS of $8.25-8.75 - not including the acquisition of PreCision Dermatology - revenue of $8.2-8.6B, and adjusted cash flow from operations of $2.4-2.6B.
  • Valeant expects to raise its outlook once it has closed the PreCision deal. (PR)
  • Previous
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs